Plain-English translation of NCT05679024 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing apixaban, a blood-thinning medication, to see if it can safely prevent strokes in people with stage 5 chronic kidney disease (the most advanced stage) who also have atrial fibrillation, a type of irregular heartbeat. Currently, doctors are unsure whether this medication is safe and effective for this specific group of patients. The study will follow about 1,400 people across several European countries to compare those taking the medication with those receiving standard care without it.
People with advanced kidney disease who have irregular heartbeats face a high risk of stroke, but past studies haven't clearly shown whether this medication is safe for them. Doctors need solid evidence to know whether the benefits of stroke prevention outweigh potential bleeding risks in this vulnerable group.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would be randomly assigned to either take the medication twice daily along with your regular care, or to receive standard care without this blood thinner. You would visit the study clinic for check-ups to monitor your health, kidney function, and any bleeding or clotting concerns. The study team will track your health outcomes over time to see whether the medication helps prevent strokes without causing too much bleeding.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Finland
Iceland
Norway